A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.

To examine the efficacy of intensified maintenance chemotherapy, we conducted a prospective multicenter trial in adult patients with newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Of the 302 registered, 283 patients were assessable and 267 (94%) achieved complete remission. Predicted 6-year overall survival in all assessable patients and disease-free survival in patients who achieved complete remission were 83.9% and 68.5%, respectively. A total of 175 patients negative for PML-RARalpha at the end of consolidation were randomly assigned to receive either intensified maintenance chemotherapy (n = 89) or observation (n = 86). Predicted 6-year disease-free survival was 79.8% for the observation group and 63.1% for the chemotherapy group, showing no statistically significant difference between the 2 groups (P = .20). Predicted 6-year survival of patients assigned to the observation was 98.8%, which was significantly higher than 86.2% in those allocated to the intensified maintenance (P = .014). These results indicate that the intensified maintenance chemotherapy did not improve disease-free survival, but rather conferred a significantly poorer chance of survival in acute promyelocytic leukemia patients who have become negative for the PML-RARalpha fusion transcript after 3 courses of intensive consolidation therapy.

[1]  Haifa Hamdi,et al.  Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. , 2007, Blood.

[2]  M. Shibuya,et al.  Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. , 2007, Blood.

[3]  S. E. Jacobsen,et al.  Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy. , 2006, Blood.

[4]  H. Dombret,et al.  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Mitani,et al.  A randomized, postremission comparison of four courses of standard‐dose consolidation therapy without maintenance therapy versus three courses of standard‐dose consolidation with maintenance therapy in adults with acute myeloid leukemia , 2005, Cancer.

[6]  N. Asou.  Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia. , 2005, Internal medicine.

[7]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[8]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Ohno,et al.  Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate , 2003, Leukemia.

[10]  M. Yoder,et al.  Functional p85α gene is required for normal murine fetal erythropoiesis , 2003 .

[11]  E. Estey,et al.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.

[12]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[13]  M. Baccarani,et al.  Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. , 2002, Blood.

[14]  F. Mandelli,et al.  Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. , 2002, Blood.

[15]  M. Tallman,et al.  Acute promyelocytic leukemia: evolving therapeutic strategies. , 2002, Blood.

[16]  O. Yamada,et al.  Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG) , 2001, Cancer Chemotherapy and Pharmacology.

[17]  J. Esteve,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[18]  W. Hiddemann,et al.  Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia , 2000, Leukemia.

[19]  T. Naoe,et al.  Role of P‐glycoprotein in all‐trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA , 2000, British journal of haematology.

[20]  F. Appelbaum,et al.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. , 2000, Blood.

[21]  J. Esteve,et al.  A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute Promyelocytic Leukemia , 1999 .

[22]  F. Mandelli,et al.  Therapy of molecular relapse in acute promyelocytic leukemia. , 1999, Blood.

[23]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[24]  T. Naoe,et al.  Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. , 1999, International journal of hematology.

[25]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[26]  J. Esteve,et al.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. , 1999, Blood.

[27]  P. Pandolfi,et al.  Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide , 2001 .

[28]  J. Miguel,et al.  Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia , 1998 .

[29]  F. Mandelli,et al.  Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial , 1998 .

[30]  P. Fenaux,et al.  Retinoic Acid Syndrome , 1998, Drug safety.

[31]  F. Mandelli,et al.  Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. , 1998, Blood.

[32]  O. Yamada,et al.  Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Miguel,et al.  Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1998, Blood.

[34]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[35]  T. Naoe,et al.  Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. , 1997, Blood.

[36]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[37]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[38]  D. Sentero,et al.  Retinoic acid syndrome in acute promyelocytic leukemia. , 1997, Wisconsin medical journal.

[39]  P. Thall,et al.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Barbui,et al.  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.

[41]  T. Naoe,et al.  Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Braziel,et al.  Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. , 1995, Blood.

[43]  T. Naoe,et al.  Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). , 1995, Leukemia.

[44]  M. Tanimoto,et al.  All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. , 1995, Blood.

[45]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[46]  T. Naoe,et al.  Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML‐87 study of the Japan adult leukemia study group , 1993 .

[47]  A. Ganser,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. , 1993, Blood.

[48]  E. Dmitrovsky,et al.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Goldstein,et al.  Durable power of attorney for health care. A survey of senior center participants. , 1992, Archives of internal medicine.

[50]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[51]  H. Kantarjian,et al.  Role of maintenance chemotherapy in acute promyelocytic leukemia , 1987, Cancer.

[52]  R. Berger,et al.  [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]. , 1984, Nouvelle revue francaise d'hematologie.